TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06875960: A Continuation Protocol for Deucravacitinib in Patients With Patients With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study

Sponsor: Bristol-Myers Squibb · Phase: PHASE4 · Area: IMMUNOLOGY · Target Enrollment: 35 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$5,740,800

Rescue Site Savings

+$3,781,200

Unlock Full NCT06875960 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06875960 Rescue Dossier →